All In Biotech

Drug Trial Radar · NCT06329401

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of Pirfenidone Solution for Inhalation (AP01) in Participants With PPF

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 398 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

398

Actual

Start

Apr 3, 2024

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
Avalyn Pharma Inc.Industry
Sponsor type
Industry
Collaborators
DevPro Biopharma
First posted
Mar 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.

Conditions

  • Pulmonary Fibrosis
  • Progressive Pulmonary Fibrosis
  • Pulmonary Fibrosis Secondary to Systemic Sclerosis
  • Pulmonary Fibrosis, Interstitial Lung Disease
  • Interstitial Lung Disease
  • Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)
  • Interstitial Lung Disease in Patients With Rheumatoid Arthritis
  • Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere
  • Hypersensitivity Pneumonitis
  • Interstitial Lung Disease With Systemic Sclerosis

Interventions

  • AP01Drug

    Oral inhalation solution

  • PlaceboOther

    Placebo oral inhalation solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the effect of AP01 high dose twice a day (BID) or AP01 low dose twice a day (BID) compared to placebo twice a day (BID)Time frame: Week 52

Locations

154 sites in 14 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Mayo Clinic- Scottsdale

    Scottsdale, Arizona

  • University of Southern California

    Los Angeles, California

  • Cedars-Sinai

    Los Angeles, California

  • UCLA

    Los Angeles, California

  • Newport Native MD, Inc.

    Newport Beach, California

  • Paradigm Clinical Research - Redding

    Redding, California

  • University of California - San Francisco

    San Francisco, California

  • University of Colorado, Anschutz Medical Campus

    Aurora, Colorado

  • National Jewish Health

    Denver, Colorado

  • UCONN Health

    Farmington, Connecticut

  • Yale University

    New Haven, Connecticut

  • Clinical Site Partners, LCC

    Leesburg, Florida

  • Renstar Medical Research

    Ocala, Florida

  • Clinical Site Partners

    Winter Park, Florida

  • Piedmont Healthcare, Inc.

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • Endeavor Health

    Evanston, Illinois

  • Loyola University Medical Center

    Maywood, Illinois

  • The University of Kansas Medical Center

    Kansas City, Kansas

  • University of Maryland

    Baltimore, Maryland

  • Johns Hopkins University

    Baltimore, Maryland

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Hannibal Regional Healthcare System

    Hannibal, Missouri

  • Northern Westchester Hospital

    Mount Kisco, New York

  • Northwell Health - Mount Kisco

    Mount Kisco, New York

  • NYU Langone Health

    New York, New York

  • Weill Cornell

    New York, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Columbia University

    New York, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Duke University

    Durham, North Carolina

  • Piedmont HealthCare, PA

    Statesville, North Carolina

  • Accellacare

    Wilmington, North Carolina

  • Southeastern Research Center

    Winston-Salem, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

Showing 40 of 154 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.